LifeScience Antibody Drug Conjugates
Alphamab Oncology and CSPC Dose First Patient in Phase III Trial of JSKN003 for HER2-Positive Breast Cancer
Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has...
February 28, 2025 | News
Akeso Enrolls First Patient in Phase I Trial for HER3-Targeting ADC AK138D1 in Australia
Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in...
February 28, 2025 | News
WuXi XDC Expands Partnership with LigaChem to Accelerate Next-Gen ADC Development
WuXi XDC Cayman Inc. ("WuXi XDC", or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organiz...
February 26, 2025 | News
Akeso, Summit Therapeutics, and Pfizer Join Forces to Advance Ivonescimab-ADC Combinations in Solid Tumor Trials
Akeso, Inc. announced that its partner on ivonescimab, Summit Therapeutics Inc. has entered into a clinical trial collaboration with Pfizer Inc...
February 25, 2025 | News
Harbour BioMed and Insilico Medicine Partner to Accelerate AI-Driven Antibody Discovery
Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on...
February 21, 2025 | News
RemeGen Presents Promising Phase II Trial Results for Disitamab Vedotin and Toripalimab in Muscle-Invasive Bladder Cancer at ASCO GU 2025
RemeGen Co., Ltd. (RemeGen) has announced new efficacy and safety data from the Phase II clinical trial (NCT05297552, Study ID: RC48-C017) evaluating Disit...
February 17, 2025 | News
Akeso Receives IND Approval in China for AK139, the First IL-4Rα/ST2 Bispecific Antibody
Akeso, Inc. is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (...
February 14, 2025 | News
DAAN Biotherapeutics and LigaChem Biosciences Forge Exclusive Licensing Deal to Advance ADC Development
DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, has signed an exclusive licensi...
February 14, 2025 | News
OnCusp Therapeutics Secures FDA Fast Track Designation for CUSP06 in Platinum-Resistant Ovarian Cancer
OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validat...
February 13, 2025 | News
China's BioRay Secures NMPA Nod for Clinical Trials of BR111, a First-in-Class Anti-ROR1 ADC
BioRay Pharmaceutical Co., Ltd. ("BioRay") announced that the National Medical Products Administration (NMPA) has accepted the clinical trial application f...
February 11, 2025 | News
GI Innovation and LaNova Medicines Join Forces for Breakthrough Pancreatic Cancer Combination Therapy
GI Innovation (KQ:358570) announced that it signed a Memorandum of Understanding (MOU) with LaNova Medicines (LaNova) for the development o...
January 23, 2025 | News
Lepu Biopharma Partners with ArriVent BioPharma for Global Development of MRG007, a Promising ADC for GI Cancers
Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) announced that it has entered into an exclusive licensing agreement with ArriVent BioPharma, Inc.&...
January 23, 2025 | News
InnoCare Pharma, KeyMed Biosciences, and Prolium Bioscience Partner on $520M Global Licensing Deal for CD20xCD3 Bispecific Antibody
InnoCare Pharma and KeyMed Biosciences announced that the two companies, together with their joint venture, have jointly entered into an exclusive li...
January 21, 2025 | News
Axcynsis Therapeutics Secures FDA Clearance for First ADC Program Utilizing AxcynDOT™ Technology
AT03-65 is the first program utilizing AxcynDOT™, a proprietary payload with a differentiated mechanism of action, to enter clinical d...
January 15, 2025 | News
Most Read
- Pioneering Precision: Top 15 Clinical and Lab Diagnostic Companies to Watch in 2025
- 2025 Pharma and Medical Device Trends for Manufacturing Leaders
- 25 High-Value Drugs Losing Patent Protection in 2025: What It Means for Healthcare
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Top Management Shakeups of 2024: Redefining Pharma, Biopharma, and Biotech Leadership
- James Park Joins South Korean LOTTE BIOLOGICS as New CEO to Lead Global Expansion
- Australia Takes the Lead: Moderna Opens Southern Hemisphere’s First mRNA Manufacturing Facility in Victoria
- Eli Lilly Announces $3 Billion Expansion in Wisconsin to Boost Global Medicine Production
- Ngee Ann Polytechnic Partners with Merck Singapore to Elevate Biopharmaceutical Education
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Life Sciences CEOs Bet Big on AI and Workforce Growth Despite Economic and Industry Headwinds
News
